Secondary Logo

Institutional members access full text with Ovid®

90-90-90 HIV targets

implications for HIV-associated tuberculosis

Granich, Reubena; Gupta, Somyab

Current Opinion in HIV and AIDS: November 2018 - Volume 13 - Issue 6 - p 528–537
doi: 10.1097/COH.0000000000000498
TUBERCULOSIS AND HIV: Edited by Richard E. Chaisson and Haileyesus Getahun

Purpose of review The HIV and Mycobacterium tuberculosis syndemic remains a major global public health threat. HIV and tuberculosis (TB) global targets have been set. Success will depend on achieving combined disease control. We explore current policy, economic investment, and disease control strategies for HIV, TB, and HIV-associated TB. We review published HIV, TB, and HIV-associated TB data for 30 WHO priority countries and propose a comprehensive HIV and TB care continua.

Recent findings In 2016, people living with HIV (PLHIV) on antiretroviral treatment (ART) ranged from 13 to 84%; viral suppression ranged from 21 to 79%. Only 5% of PLHIV without TB reported a course of isoniazid preventive therapy (IPT). TB treatment success (2015) ranged from 34 to 94%. Data for the combined indicators: TB treatment success and viral suppression and IPT and ART for PLHIV are not collected. Reported 2003–2017 global international and domestic resources for TB and HIV-associated TB averaged $2.9 billion per year; cumulative total was $43 billion.

Summary Integrating HIV and TB control efforts including monitoring and evaluation systems will be necessary to end both TB and HIV. A comprehensive HIV and TB continuum supports integrated, comprehensive HIV and TB disease control efforts focused on improving both individual and public health.

aInternational Public Health Consultant, San Francisco, California, USA

bInternational Public Health Consultant, Delhi, India

Correspondence to Reuben Granich, MD, MPH, International Public Health Consultant, 4329, 20th Street, San Francisco, California 94114, USA. Tel: +1 202 615 6913; e-mail:

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.